Initiator Pharma A/sOMXSTO: INIT

Initiator Pharma To Fully Prioritize Pudafensine

· Issued by Initiator Pharma A/s

Initiator Pharma A/S OMXSTO:INIT:

  • INITIATOR PHARMA TO FULLY PRIORITIZE PUDAFENSINE

  • TO FOCUS FULLY ON ITS MOST PROMISING DRUG CANDIDATE, PUDAFENSINE

  • WILL DISCONTINUE FURTHER DEVELOPMENT OF IP2018

  • RESOURCES FROM IP2018 TO BE REDIRECTED TO PUDAFENSINE DEVELOPMENT

  • PUDAFENSINE PHASE IIA STUDY IN VULVODYNIA EXPECTED TO COMPLETE BY END 2026

  • ADDITIONAL PROOF-OF-CONCEPT DATA IN VULVODYNIA EXPECTED BEFORE YEAR-END

Earlier from Initiator Pharma A/s

All Initiator Pharma A/s news releases